Serum Free Media Market by Media (Protein Expression, Stem Cell, Hybridoma, Primary Cell, Insect Cell, Immunology and Chinese Hamster Ovary (CHO) Cell Culture Media)
Industry: Healthcare
Published Date: February-2023
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 250
Report ID: PMRREP15373
The Global revenue from the Serum Free Media market was approximately US$ 1.7 Billion in 2022, with the global market expected to grow at a CAGR of 7.8% to reach a valuation of approximately US$ 3.9 Billion by the end of 2033.
|
Market Size (2023) |
US$ 1.8 Billion |
|
Projected Market Value (2033) |
US$ 3.9 Billion |
|
Global Market Growth Rate (2023 to 2033) |
7.8% CAGR |
|
Market Share of Top 5 Countries (2022) |
56.9% |
As assessed by Persistence Market Research, biopharmaceutical companies held a market share of around 84.1% in the global market, in 2022. Overall, serum free media market sales account for around 39.5% of revenue share in the global cell culture media market, which was valued at around US$ 4.3 Billion in 2022.
The Global Serum Free Media Market recorded a historic CAGR of 6.6% in the last 7 years from 2015 to 2022.
Serum-free media (SFM) allows for the growth of a specific cell type with a specific function, such as providing growth factors and hormones for cell functions and growth promotion in the cell culture under predetermined conditions.
The growth of research and development is increasing owing to increased research and development activities with extensive use of animal component free media like absence of clotting proteins, interfering components, glucose, insulin, transferrin, and selenium that affect cell growth. The cell culture has a vast use in disease diagnosis, emphasizing their importance in healthcare.
It ascertains the safe and effective application of upgraded cell culture and cell therapy methods. Other uses of SFM cell cultures are cancer research, cell biology, metagenomics, molecular biology applications, and plant research. Various clinical organizations and biopharmaceutical companies are working together to find out the therapeutic applications of pharmaceutical drugs in several disease conditions in order to facilitate systematic diagnosis, appropriate dosage and treatment selection, and treatment monitoring.
Biopharmaceutical companies contribute to the healthcare industry by focusing on biopharmaceutical production with superior efficacy to conventional drugs for the treatment of infectious and chronic diseases. The rise of advanced manufacturing technologies, continuous improvement in manufacturing scalability, flexibility, and alternative downstream processes are some of the key drivers of increased biopharmaceutical production.
Rising demand for vaccines and monoclonal antibodies has resulted in increased demand for SFM techniques. Increased emphasis and expenditure on research and development capabilities in cell-based research is creating even more lucrative serum free media market growth opportunities. Advances in genomic and proteomic profiling, genetic engineering, and recombinant DNA technology have boosted demand for serum free media further.
Biopharmaceutical companies collaborating with various academia for gaining knowledge based resources and research collaborations for improvising cell media development and final product manufacturing. Increasing number of contract research (CRO) labs and biopharmaceutical companies is increasing the demand for SFM. This leads key players into expanding their product offering with multiple serum media, with fewer genetic variations.
All these potential trend factors are contributing the expansion of the serum free media market in the forecast period.
“Superior Cell Growth and Ease of Contamination Free Purification”
Because the cell-specific serum-free media are homogeneous, it promotes superior cell growth and reduces uneven cell growth. As a result, cell culture and increased productivity are combined to produce, research, and develop biopharmaceuticals.
The precise amounts of each component added to every SFM composition are known, making it a defined media that consistently promotes improved cell culture growth. SFM is a recommended medium for cell growth because it removes the possibility of contamination during an experiment by being free of fungi, bacteria, and other elements that can cause disease.
In comparison to serum media or undefined media, the specified nature of SFM typically facilitates a simpler purifying procedure. SFM commonly involves additional identified ingredients that promote greater cell proliferation. The known additional composition of SFM makes the purification process simple. It is significantly easier to control the cell environment in SFM due to the lower protein concentration, which also lowers contamination of downstream processing.
In SFM, the protein concentration is low, which significantly decreases the chances of indifferentiation in between serum protein and recombinant protein during recombinant protein research.
Academic research also favors unconventional methods to discover Biopharmaceutical treatments for diseases.
Because of their greater effectiveness in treating chronic diseases, biopharmaceuticals are increasingly being used as the treatment of choice, which raises the amount of these drugs produced. The utilization of biopharmaceuticals in the healthcare sector is increasing at an unprecedented rate due to constantly changing production techniques, molecules, and several other variables, which is anticipated to open up a wide range of opportunities for the growth of the serum free media market.
For instance, because biopharmaceutical leaders are leading in vitro research and development in the pursuit for vaccines and antivirals, the COVID-19 epidemic has had a favorable impact on the market outlook for serum free media.
“Expensive Production Process and High Research and Development Costs”
While serum is a crucial component that offers natural growth mediators for cell culture growth, it is substituted in serum-free media by other predetermined components. In order to improve cell development in the culture, SFM is added along with artificial growth factors.
The quantity of growth mediators needed for different types of cell growth does not match since the necessity for growth factors varies depending on the cell type, which leads to slower growth.
For SFM, each additional component must be known together with its function and quantity in order for it to qualify as a defined media. Not all cell culture growth types respond well to a particular form of SFM.
When compared to serum media, developing cell-specific SFM and screening the composition after each stage make it a tedious, expensive, and time-consuming process, which drives up the expenses of research, development, and production.
SFM production takes time, and developing it for a particular cell type typically makes it take more time. The demand for SFM is impacted by the specific growth mediator requirements for different types of cells to sustain growth.
Due to cell-specific SFM, it affects the availability of SFM in different geographies. The regulatory procedures including screening for each component of SFM further delays the availability, thus hampering market expansion.
Why is the United States Market Booming?
“Presence of Established Players and CROs”
The United States accounted for around 28.0% of the global market in 2022, due to advancements in cell-based assays, such as cellular expression, pluripotent stem cell research, and cytotoxicity assay, etc.
This is primarily due to the presence of numerous biopharmaceutical companies in the area, as well as research funding for cell and stem cell-based products, the presence of numerous CROs, and a well-established healthcare infrastructure.
Other factors such as the increased use of serum free media culture to develop vaccines for chronic diseases, as well as the rise in demand for various recombinant proteins, contribute to the growth of the serum free media industry in the country.
Will the Germany Be a Lucrative Market for Serum free media?
“Growing Private and Government Investments in Biopharmaceutical and Genetics Industry”
The German market held around 7.1% market share of the global market in 2022.
Affordability is the main issue facing the global serum-free media market. Researchers and diagnosticians in both developed and developing nations use this technology frequently because it delivers accurate information and prompt results. The cost of serum free medium technology is higher than the cost of other cell culture technologies as a result.
Serum free media, a rapidly expanding area of biotechnology and biopharma in Germany with university institutions, allows research scientists to monitor and evaluate the interactions between cells and pathogens like viruses and bacteria, study the effects of drugs, and look at the ageing process. Government research organizations invest modest amounts of money in areas like gene editing. These elements are boosting the serum-free media industry in Germany.
How is China Emerging as a Prominent Market?
"High Prevalence of Disease, Regulatory Support, Low Production Costs, and Rising Research Efforts”
China held a market share of about 9.2% of the global market in 2022.
In China, the prevalence of infectious and chronic diseases is rising despite all precautions and personal hygiene practices. The prevalence of infectious diseases has led to improvements in research and development using serum free media technology, which is anticipated to drive the total serum free media market.
Government support for the production of vaccines based on cell cultures, amiable regulatory requirements, low manufacturing costs, increasing research, development capabilities with the aid of key manufacturers increased focus on collaboration with China, and rising stem cell and cell culture therapies, will all contribute to the market expansion in China.
Which Media is Driving Demand within the Global Market?
“Ease of Large Scale Manufacturing with CHO Cells”
Because of its benefits, including high productivity and ease of culture, Chinese hamster ovary (CHO) cell culture media held around 19.7% share of the global market in 2022. Nearly 50 biotherapeutics have been employed in CHO cell cultures, a well-established genetic engineering technique with minimal viral susceptibility that has already received approval in the U.S. and EU.
CHO cells have appeared as the gold standard in the antibody production process due to their ability to produce complex proteins similar to those found in humans. They are ideal for large-scale manufacturing due to their high tolerance for changes in cell density, oxygen levels, pH, or temperature. This contributes to their high stability and adaptability for protein-free, animal-free, and serum-free culture conditions. Thus, biopharmaceutical firms are adopting CHO cell culture media for production of biomedicines, which increases the global segment share.
Which End User Primarily Aids to the Expansion of the Global Market?
“Growing Production of Novel Biopharmaceuticals”
Biopharmaceutical companies hold a market share of around 84.1% of the global market share in 2022, owing to expanded manufacturing capacities with increased prevalence of infectious and chronic disease, and demanding novel therapeutic drugs.
Revolution in the life science sectors and increased investment in research and development by private and public sectors for production of vaccines, monoclonal antibodies, and other therapeutic proteins for treatment of infectious and chronic diseases like COVID-19 and cancer respectively are factors promoting the growth within the segment, globally.
The development in the life sciences sector has continued to increase its business through product releases, organic investments, and acquisitions. Biopharmaceutical businesses are employing key approaches to accomplish business growth by expanding manufacturing facilities for better regional footprints.
A few examples of products launched by biopharmaceutical companies:
Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the serum free media market, which are available in the full report.
|
Attribute |
Details |
|
Forecast Period |
2023 to 2033 |
|
Historical Data Available for |
2017 to 2022 |
|
Market Analysis |
US$ Million for Value |
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Covered |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon Request |
Media:
End User:
Region:
To know more about delivery timeline for this report Contact Sales
The global market is valued at around US$ 1.7 Billion in 2022.
Sales of the market are set to witness growth at a CAGR of 7.8% and be valued at around US$ 3.9 Billion by 2033.
Demand for the global market increased at a 6.6% CAGR from 2015 to 2022.
The U.S., China, Germany, the U.K., and Japan account for most demand within the market, and were holding around 56.9% market share in 2022.
The U.S. accounts for around 28.0% share of the North American market in 2022.
Europe accounts for around 29.0% share of the global market in 2022.
The China market held a share of about 9.2% in the global serum free media market in 2022.
The serum free media industry in India held a 5.3% market share in 2022.
Rising prevalence of chronic and infectious diseases, growing investments in research, and increasing production of novel biologics, are the key factors propelling growth within the global market.
Stem Cell Providers, Merck KGaA, GE Healthcare, Lonza, Corning Incorporated, Irvine Scientific, STEMCELL Technologies Inc., PAN Biotech, MP Biomedicals, LLC, PromoCell GmbH, and Sartorius AG, are the key players within the global market.
